홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
SGMT
#3702
Sagimet Biosciences Inc. Series A Common Stock
5.9
3
USD
+7.04%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+7.04%
월간 변동
+12.74%
6달 변화
-24.07%
년간 변동율
+178.40%
이전 종가
5.5
4
Open
5.8
7
Bid
Ask
Low
5.8
7
High
5.9
5
양
46
마켓
주식
헬스케어
SGMT
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
32.2 M
32.2 M
32.52 M
32.52 M
32.59 M
—
Valuation ratios
Enterprise value
—
—
—
—
—
—
Price to earnings ratio
-3.1
-1.83
-4.12
-3.81
-3.75
-13.51
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-3.32
-2.05
-4.5
-4.9
-4.19
-15.65
Price to book ratio
0.91
0.16
0.41
0.4
1.72
2.69
EBITDA 비율에 대한 기업 가치
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.1
-0.12
-0.08
-0.1
-0.08
-0.38
Return on equity %
-0.1
-0.13
-0.08
-0.11
-0.09
-0.4
Return on invested capital %
—
—
—
—
-988.02
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
34.3
20.41
17.55
13.06
22.82
73.84
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.35
-0.45
-0.28
-0.31
-0.37
-1.41
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
5.06
4.49
4.21
3.87
3.5
16.06
Net current asset value per share
4.87
4.54
3.95
3.68
3.6
15.77
Tangible book value per share
4.97
4.32
4.04
3.67
3.44
15.48
Working capital per share
4.73
4.31
3.73
3.4
3.44
14.88
Book value per share
4.97
4.32
4.04
3.67
3.44
15.48
뉴스
시티즌, MASH 진전 관련 Sagimet Biosciences 투자의견 재확인
Citizens reiterates Sagimet Biosciences stock rating on MASH progress
오펜하이머, MASH 임상 진행에 사지메트 주식 등급 재확인
Oppenheimer reiterates Sagimet stock rating on MASH trial progress
사지메트, 여드름 치료제 3상 안전성 데이터 발표 후 주가 상승
Sagimet stock rises after positive Phase 3 safety data for acne drug
Ascletis reports positive long-term safety data for acne drug denifanstat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)
Sagimet reports positive Phase 1 results for MASH combination therapy
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Sagimet Biosciences executive chairman sells $290k in shares
Sagimet 바이오사이언스 목표 주가, Citizens, 35달러로 상향